F-1: Otsaw Limited Files for Nasdaq IPO to Fuel Global Robotics Expansion and AI Innovation

Singapore-based robotics firm Otsaw Limited is pursuing an initial public offering on the Nasdaq Capital Market to raise capital for expanding its autonomous mobile robot solutions, enhancing core AI technologies, and increasing global market presence.

Summary

• Otsaw Limited, founded in 2015, specializes in AI-enabled autonomous mobile robots (AMRs) and robotics solutions for facilities management, including security, disinfection, last-mile delivery, and healthcare.
• The company reported revenues of US$5.3 million for the fiscal year ended April 30, 2024, a 3% increase from US$5.1 million in the prior year.
• Net losses for the fiscal year ended April 30, 2024, were US$6.5 million, a slight improvement from US$6.7 million in the previous fiscal year.
• For the six months ended October 31, 2024, revenues decreased to US$1.8 million from US$2.8 million in the same period of 2023, primarily due to cyclical AGV project deliveries and a transition from old to new robot models.
• Net losses for the six months ended October 31, 2024, increased to US$3.3 million from US$2.9 million in the prior comparable period, driven by decreased revenue and increased operating expenses related to IPO activities and R&D personnel costs.
• The company's gross profit margin improved to 31.6% in FY2024 from 24.7% in FY2023, mainly due to larger, more complex projects and improved cost controls for services.
• Service and maintenance contracts are the primary revenue driver, accounting for 85.3% of total revenues for the six months ended October 31, 2024.
• Otsaw operates a dual-class share structure, with CEO Ling Ting Ming indirectly owning the sole Class B Ordinary Share, which grants him 60% of the total voting power, ensuring concentrated control post-IPO.
• The company plans to use the IPO net proceeds for acquisitions, strategic alliances, joint ventures (20%), expansion of production capacity and inventory (40%), market expansion in the US, UK, Europe, Asia, and Australia (10%), research and development (10%), and working capital (20%).
• Otsaw has established international distribution channels and partnerships in over 20 countries, with a focus on expanding its presence in the United States, Canada, the United Kingdom, Australia, and GCC countries.
• The company's product portfolio includes the O-R3 security patrol AMR, Camello+ multi-purpose delivery and security AMR, TransCar healthcare intralogistics AGVs, and UV-C disinfection systems (AirGuard, TreX, O-RX).

Sentiment

Score: 4

Explanation: The company shows promising technological innovation and market positioning in a growing industry, with increasing gross margins. However, it faces significant financial challenges, including recurring losses, negative operating cash flow, and a substantial working capital deficit, raising going concern doubts. Recent revenue decline in the latest six-month period and reliance on related party financing add to the financial risk. While growth strategies are clear, execution and overcoming financial hurdles are critical.

Positives

• Revenue increased by 3% year-over-year from US$5.1 million in FY2023 to US$5.3 million in FY2024, driven by service and maintenance and robot sales.
• Net losses decreased from US$6.7 million in FY2023 to US$6.5 million in FY2024, indicating improved operational efficiency.
• Gross profit margin significantly improved to 31.6% in FY2024 from 24.7% in FY2023, attributed to higher margins on complex projects and better cost controls.
• The company has a diversified revenue model, with a strong and growing emphasis on recurring service and maintenance contracts (85.3% of 6M FY2025 revenue).
• Strategic joint venture with Swisslog Healthcare provides immediate market access and customer base in European and APAC healthcare sectors, a high-barrier-to-entry market.
• Proprietary core software technologies, including patented 3D SLAM, Sensor Fusion, and AI/Machine Learning, provide a competitive advantage and scalability for diverse applications.
• Plans to commercialize Autonomous Navigation System (ANS) Version 3, 'Odyssey,' as a universal software solution for third-party AMRs, potentially opening significant new revenue streams in the US$150 billion global robotic software market by 2034.
• Expansion of production capacity to 15 units per month by Q3 2025 aims to achieve cost efficiencies and competitive pricing through economies of scale.
• Secured a US$2 million contract with a public hospital in Singapore (SingHealth Group) for TransCar AGVs, with phased payments tied to project milestones.
• The company has a visionary and experienced management team with extensive industry expertise, including founder and CEO Ling Ting Ming with over 27 years of experience.

Negatives

• The company has a history of recurring net losses (US$6.5 million in FY2024, US$6.7 million in FY2023) and accumulated losses of US$25.1 million as of October 31, 2024.
• Auditors have raised substantial doubt about the company's ability to continue as a going concern due to continuing losses and a net working capital deficit of US$12.4 million as of October 31, 2024.
• Negative cash flow from operating activities persists, with US$1.5 million outflow for the six months ended October 31, 2024, and US$2.3 million for FY2024.
• Revenue for the six months ended October 31, 2024, decreased by 35.8% to US$1.8 million compared to US$2.8 million in the prior comparable period, primarily due to cyclical AGV project deliveries and sales loss during model transitions.
• Sales of robots revenue decreased by 48.9% for the six months ended October 31, 2024, due to phasing out of old models and new models not yet being on sale.
• The company is dependent on a small number of key customers for a significant portion of its service and maintenance revenue, with the top three customers accounting for 21.79%, 11%, and 17.5% of sales for the six months ended October 31, 2024.
• Reliance on Reis Robotics as a single-source supplier for TransCar AGV production until June 30, 2025, poses supply chain risks and potential production delays.
• The company has limited experience maintaining or servicing its products at a large scale, which could lead to increased costs and customer dissatisfaction as operations expand.
• The commercial robotic market is in early stages of customer adoption, and large-scale application of autonomous robots in facilities management is unproven, making demand hard to predict accurately.
• Increased finance costs, rising to US$1.41 million in FY2024 from US$0.69 million in FY2023, primarily due to an increase in the average interest rate on director loans from 6% to 12%.
• The management team lacks experience in managing a U.S. public company, which could lead to challenges in regulatory compliance and investor relations.

Risks

• The company is an early-stage company with a history of losses and expects to incur significant expenses for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern due to continuing losses and limited working capital.
• The company has yet to achieve positive operating cash flow, and its ability to generate positive cash flow is uncertain given projected funding needs.
• Significant investments in research and development may not achieve expected returns, and new products may not gain market acceptance.
• The company's limited operating history makes it difficult to evaluate its business, prospects, and future viability.
• Future capital needs may require selling additional equity or debt securities, potentially resulting in substantial dilution or significant debt service obligations.
• The ability to manufacture, assemble, and produce products on a large scale is unproven, and delays could harm the business.
• The commercial robotic market is in early stages of customer adoption, and broad acceptance of products in facilities management is unproven.
• Demand for products is hard to predict accurately, and inability to forecast effectively could materially impact operating results and financial condition.
• Targeting large corporations with substantial negotiating power and potentially competitive internal solutions may adversely affect prospects and results.
• Expanding operations into new regions or countries with no prior operating experience may lead to difficulties and increased expenses.
• Operating in a rapidly evolving and competitive industry subject to technological evolution could cause market share decline and negatively impact results.
• Dependence on the global supply chain and experienced supply chain constraints (e.g., semiconductor shortages, high inflation, geopolitical events) could increase costs and delay product delivery.
• Reliance on single, sole, or limited source suppliers (e.g., Reis Robotics for TransCar systems) could cause production delays and revenue loss.
• Failure to build and maintain the Otsaw brand, or negative publicity, could materially and adversely affect product acceptance and business.
• Limited experience operating robots in a variety of environments, and increased deployment may lead to collisions, liability, and negative publicity.
• Design flaws, unknown defects, errors, glitches, malfunctions, connectivity issues, or user errors in products could result in recalls, claims, injuries, property damage, and safety concerns.
• Subject to stringent and changing laws, regulations, and standards related to data privacy and security in various jurisdictions.
• Cybersecurity risks to operations, IT infrastructure, systems, software, and data could result in loss of confidence and harm business.
• Unauthorized access or control of AMR and robotics systems could result in loss of confidence and harm business.
• Acquiring other businesses, forming joint ventures, or making other investments could negatively affect operating results, cause dilution, or increase debt.
• Failure to manage significant business and operational expansion effectively could materially and adversely affect business, prospects, financial condition, and operating results.
• Entering into strategic alliances, such as the joint venture with Swisslog Healthcare, exposes the company to risks, including potential disputes and reliance on partners.
• The put option under the Swisslog Healthcare joint venture could require the company to purchase Swisslog Healthcare's equity interests, adversely affecting liquidity and financial condition.
• Loss of key personnel or failure to attract and retain highly qualified personnel could harm the business.
• Management team lacks experience in managing a U.S. public company, leading to potential challenges in regulatory compliance and investor relations.
• Developments in the social, political, regulatory, and economic environment (e.g., natural events, wars, health epidemics) in operating countries may have a material adverse impact.
• Global economic conditions could materially adversely impact demand for products and services.
• Subject to risks associated with international operations, including unfavorable regulatory, political, tax, and labor conditions.
• Potential involvement in legal proceedings could have a material adverse effect on business, operating results, or financial condition.
• Exposure to foreign exchange risk arising from various currency exposures, with fluctuations affecting financial results.
• Imposition of barriers to trade, escalation of trade disputes, and changes to trade policy, tariffs, and import/export regulations may have a material adverse effect.
• Subject to anti-corruption, anti-bribery, anti-money laundering, financial, and economic sanctions laws, with noncompliance leading to fines and penalties.
• Failure of internal controls over financial reporting could harm business and financial results.
• Environmental laws and regulations and unforeseen costs could negatively impact future earnings.
• Ability to obtain and maintain protection for intellectual property is crucial; failure to do so could diminish brand value and adversely affect business.
• May not be able to protect intellectual property rights in all countries, especially developing ones.
• May be subject to intellectual property claims in the future, which are costly to defend and could limit technology use.
• Use of other parties' software, including open source, could lead to inability to continuously use such software or intellectual property.
• The dual-class share structure concentrates voting control with the CEO, limiting influence of Class A shareholders.
• As a controlled company and foreign private issuer, the company may choose exemptions from Nasdaq corporate governance rules, potentially affording less protection to shareholders.
• Class A Ordinary Shares may be thinly traded, making it difficult to sell at or near ask prices.
• No prior public market for Class A Ordinary Shares, and no assurance of a liquid public market developing.
• Failure to satisfy or continue to satisfy Nasdaq Capital Market listing requirements could lead to delisting.
• Nasdaq may apply additional and more stringent listing criteria due to small public offering and large insider holdings.
• The trading price of Class A Ordinary Shares may be volatile, potentially resulting in substantial losses.
• Recent IPOs with comparable public floats have experienced extreme volatility, which may apply to Otsaw.
• Exercise of options or issue of awarded shares under the Equity Incentive Plan may result in dilution.
• If securities or industry analysts publish inaccurate or unfavorable research, the market price and trading volume could decline.
• Short selling may drive down the market price of Class A Ordinary Shares.
• Broad discretion in the use of net proceeds from the public offering, which may not be used effectively.
• No expectation of paying dividends in the foreseeable future, requiring reliance on price appreciation for investment return.
• Shares eligible for future sale may adversely affect the market price.
• New investors will experience immediate and substantial dilution.
• Incurrence of increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Uncertainty regarding classification as a Singapore tax resident could have tax implications.
• The company has not initiated regulatory certification processes (UL, FCC) for most product lines, which could impact marketability in the US and Europe.

Future Outlook

Otsaw Limited plans to advance its core software technologies, including the commercialization of its Autonomous Navigation System (ANS) Version 3, 'Odyssey,' targeted for launch in 2028, which is envisioned as a universal software system for third-party AMRs. The company aims to expand its production capacity to 15 units per month by Q3 2025 to achieve cost-efficient manufacturing and competitive pricing for its next-generation Transcar 5.0 and Camello+ solutions. Transcar 5.0 production is expected to launch in 2025, with first commercial deployment targeted for Q1 2026. Global market presence will be increased in security and healthcare facilities management industries through expanding sales and marketing teams, strengthening distribution networks, and pursuing strategic alliances, acquisitions, investments, and partnership opportunities, particularly in the United States, Canada, the United Kingdom, Australia, and GCC countries. The company expects to incur losses and increasing expenses in the foreseeable future as it invests heavily in R&D, production, and market expansion.

Management Comments

• "We believe your background and experience will be a significant asset to the Company and we look forward to your participation as an independent director in the Company." (Offer letters to independent directors)
• "We believe our AMRs, UV-C LED disinfections, and intralogistics robotics ecosystems will rapidly expand and continue to play a significant role in this post-pandemic world, where the labor shortage and challenges have been critically exposed, and where the power of automation, robots and AI is being realized in the facilities management industry."
• "We believe that our RaaS model enables us to deliver significant value to our customer end-users at a low cost."
• "We envision that the RaaS model would be attractive to the end-users and accelerates market adoption of our products as it lowers the upfront costs of deployment, shifts capital expenditures to operating expenditures, and provides the operational and technical support with the ability to upgrade any leased product as new technologies emerge."
• "We believe we are one of the first players in the robotics industry to commercialize AMR solutions targeting the facilities management industry."
• "We aspire to create meaningful, innovative, and reliable robots that make peoples lives easier and help our customers thrive."
• "We believe the world is entering a new era where robots will become increasingly prevalent in all sectors, and thus we believe the Odyssey will expand our ecosystem coverage by integrating our core software technologies with all relevant players in the robotics industry."
• "We are confident in our ability to take advantage of current market opportunities because hospitals worldwide are expected to upgrade their intralogistics systems to solve labor shortage and productivity challenges that were particularly exposed during the COVID-19 pandemic."
• "We envision to replace the conventional labor-intensive high and low volume intralogistics, disinfection, and security patrol functions in hospital and healthcare facilities with our AI-enabled robotics and AMR solutions."
• "We believe the integration of TransCar systems with our existing AMRs and disinfection systems will provide a synergized solution to alleviate the workloads of and pressure on front-line medical workers."
• "Innovation is the key to our success as we remain on the cutting edge of machine learning and robotic autonomy."
• "We believe our brand is enhanced by knowledgeable marketing personnel who can demonstrate the unique solutions provided by our products."
• "We believe that the O-R3 is able to stand out from similar products of our competitors due to its capabilities in navigating outdoor environment and in industry applications."
• "Our UV-C disinfection systems use proprietary UV-C LED technology, which we believe delivers safer and more effective disinfection compared to traditional mercury-based systems."
• "We believe that the TransCar AGV is able to stand out from similar products of our competitors because it is multifunctional and is able to handle food, medication, linen and sterile equipment deliveries."
• "We believe that Camello+ is able to stand out from similar products of our competitors because of its modular capabilities, allowing it to be adapted for different use cases, from basic last mile logistics to critical healthcare deliveries."
• "We believe that our AMRs and robotic solutions will augment and enhance human labor."

Industry Context

Otsaw operates within the rapidly expanding global robotics market, projected to surpass USD 200 billion by 2030 (16.1% CAGR). The company specifically targets the facilities management industry, which is valued at USD 1,277.8 billion in 2023 and is expected to grow to USD 2,284.8 billion by 2032 (8.2% CAGR). This growth is driven by persistent labor shortages, rising wages, and the increasing prevalence of AMRs, robotics, and AI in sectors like healthcare logistics (7.75% global CAGR), security robotics (14.70% global CAGR), disinfection robots (19.2% global CAGR), and autonomous last-mile delivery (23.5% global CAGR). Otsaw positions itself as an early-mover and innovator in AI-enabled AMRs, aiming to disrupt traditional human-labor-intensive services by offering cost-efficient, productivity-enhancing automated solutions. The company's multi-industry focus (healthcare, logistics, security) and versatile, modular robot designs differentiate it from many niche competitors.

Comparison to Industry Standards

• Otsaw's O-R3 AMRs compete with autonomous security robot and platform developers such as Kabam Robotics Pte. Ltd., Ninebot Asia Pte. Ltd., SMP Robotics Singapore Pte. Ltd., Knightscope, Inc., and Robotics Assistance Devices, Inc. Otsaw believes its O-R3 stands out due to its outdoor navigation capabilities and industry applications.
• Otsaw's UV-C disinfection systems compete with PBA Robotics Pte. Ltd., Sesto Robotics Pte. Ltd., ST Engineering Ltd., and Pudu Technology. Otsaw highlights its proprietary UV-C LED technology for safer and more effective disinfection compared to traditional mercury-based systems, focusing on hospital-grade cleaning.
• The TransCar AGV faces competition from major robotics and automation companies globally, including Oppent S.P.A., Oceaneering International, Inc., Aetheon Inc., Mobile Industrial Robots ApS, DS Automation Ltd., MLR System GmBH, and JBT Corporation. Otsaw believes TransCar AGV's multi-functional capability (handling food, medication, linen, sterile equipment) differentiates it.
• Otsaw's Camello+ AMR competes with ground-based unmanned delivery vehicles from Starship Technologies, Kiwi Campus Inc., Robby Technologies, Inc., ZMP, Inc., Serve Robotics Inc., Aetheon Inc., and Ottonomy.io. Otsaw emphasizes Camello+'s modular capabilities for diverse use cases, from basic logistics to critical healthcare deliveries.
• The company's primary competition remains traditional human labor and facilities management service providers, against whom Otsaw aims to demonstrate value proposition and cost-efficiency through increased productivity, labor freeing, cost reduction, and enhanced robot reliability.

Management Changes

Corporate Governance

Legal Proceedings

• There are currently no material legal proceedings against the company or that have been against the company.
• The company is not aware of investigations being conducted by a governmental entity into the company.

Related Party Transactions

• Sales of goods and services to Swisslog Healthcare AG Branch Italy, Swisslog Healthcare AG Branch Netherlands, Swisslog UK, SAS Swisslog France, and Activ Technology Group (controlled by CEO Ling Ting Ming).
• Purchases of goods and services from Activ Technology Pte Ltd, Serial Microelectronics Pte Ltd, Swisslog Healthcare GmbH, Swisslog Healthcare AG Branch Germany, Swisslog Healthcare AG Branch Netherlands, Meyzer Management Advisory Pte Ltd, and SG Networks Pte Ltd.
• Loans from related parties, including the director (Ling Ting Ming), with interest rates increasing from 6% to 12% per annum from May 1, 2023.
• US$8,746,280 of related party loans were converted to share capital in January 2024.
• Deferred consideration adjustments from Swisslog Healthcare Holding AG for the acquisition of Swisslog assets, amounting to US$259,875 in FY2024 and US$486,468 in FY2023, due to unmet revenue targets.
• Otsaw Logistic Pte Ltd, a loss-making and non-core subsidiary, was sold to Mr. Ling Ting Ming (CEO) for SGD1 on January 31, 2024.
• Otsaw Swisslog Healthcare Robotics Pte. Ltd. became 100% owned by Otsaw Technology Solutions Pte. Ltd. by January 20, 2025, through the exercise of call options, with payments totaling S$2.4 million (US$1.79 million) for the three tranches, subject to revenue target adjustments.
• A net difference of 33,000 EUR in dues between Otsaw parties and Swisslog/Affiliates is payable by Otsaw in cash by December 31, 2024, with the remainder (32,847.62 EUR) included in a 1.1% monthly interest payment.

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution from the IPO. The dual-class share structure concentrates voting power with the CEO, limiting influence for Class A shareholders. The company's history of losses and going concern doubt poses significant risk to investment value. Future capital raises could further dilute ownership.
• Employees: The company plans to expand its workforce, particularly in sales, marketing, R&D, production, and customer service, creating new opportunities. However, competition for skilled talent is intense, and the company's ability to attract and retain personnel is crucial for growth. Employee stock ownership plans are in place, but previous options have lapsed.
• Customers: Benefit from advanced AI-enabled AMRs and robotics solutions designed to enhance productivity, reduce reliance on human capital, and integrate automation. The RaaS model offers lower upfront costs and comprehensive support. However, potential product defects, connectivity issues, or service delays could impact customer satisfaction and relationships.
• Suppliers: The company relies on a diverse network of suppliers, but dependence on single or limited-source suppliers for key components (e.g., Reis Robotics for TransCar, semiconductors, lithium-ion cells) creates risk. Supply chain constraints and cost inflation could affect the company's ability to meet demand and pay suppliers.
• Creditors: The company has significant outstanding loans from related parties and third parties. Its recurring losses and working capital deficit raise concerns about its ability to meet short-term obligations, as highlighted by the auditor's going concern doubt. The company's ability to secure future financing is critical for its liquidity.

Next Steps

• Complete the initial public offering and list Class A Ordinary Shares on the Nasdaq Capital Market.
• Advance core software technologies, including the development and commercialization of Autonomous Navigation System (ANS) Version 3, 'Odyssey,' with a target launch in 2028.
• Expand production capacity to 15 units per month by Q3 2025.
• Launch in-house production of Transcar 5.0 in 2025, with the first commercial deployment targeted for Q1 2026.
• Increase global presence in security and healthcare facilities management industries, particularly in the United States, Canada, the United Kingdom, Australia, and GCC countries.
• Expand the sales and marketing team and distribution network globally.
• Pursue strategic alliances, acquisitions, investments, and partnership opportunities.
• Obtain UL and FCC certifications in the United States for TransCar 5.0 after CE certification is obtained (expected Q2 2026).
• Continue to recruit and train employees, especially in sales, marketing, R&D, production, and customer services teams, in Singapore and globally.
• Build out the global help desk at the Singapore headquarters to provide technical support.
• Comply with Nasdaq listing standards, including establishing independent audit, compensation, and nominating/corporate governance committees.

Key Dates

Keywords

Autonomous Mobile Robots, Robotics, AI, Facilities Management, Security Robots, Disinfection Robots, Last-Mile Delivery, Healthcare Logistics, AGVs, UV-C LED, 3D SLAM, Sensor Fusion, Singapore, Nasdaq IPO, Otsaw